PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.52%
EBIT growth below 50% of TRAW's 34.48%. Michael Burry would suspect deeper competitive or cost structure issues.
16.52%
Operating income growth under 50% of TRAW's 34.48%. Michael Burry would be concerned about deeper cost or sales issues.
16.61%
Net income growth at 50-75% of TRAW's 26.66%. Martin Whitman would question fundamental disadvantages in expenses or demand.
17.14%
EPS growth under 50% of TRAW's 40.74%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
17.14%
Diluted EPS growth under 50% of TRAW's 40.74%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while TRAW stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
9.84%
Positive OCF growth while TRAW is negative. John Neff would see this as a clear operational advantage vs. the competitor.
13.18%
Positive FCF growth while TRAW is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2671.03%
Negative 10Y OCF/share CAGR while TRAW stands at 99.95%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.48%
5Y OCF/share CAGR is similar to TRAW's 99.88%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
83.42%
3Y OCF/share CAGR at 75-90% of TRAW's 99.44%. Bill Ackman would press for improvements in margin or overhead to catch up.
-2587.91%
Negative 10Y net income/share CAGR while TRAW is at 99.98%. Joel Greenblatt sees a major red flag in long-term profit erosion.
90.30%
5Y net income/share CAGR similar to TRAW's 99.95%. Walter Schloss might see both on parallel mid-term trajectories.
86.48%
3Y net income/share CAGR 75-90% of TRAW's 99.57%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1551.35%
Equity/share CAGR of 1551.35% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-71.69%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-47.82%
Negative 3Y equity/share growth while TRAW is at 102.22%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Asset growth well under 50% of TRAW's 144.42%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
15.36%
Under 50% of TRAW's 387.00%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-14.09%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.82%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-4.34%
We cut SG&A while TRAW invests at 24.69%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.